# DICIPLE (NCT03469960)

> Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: PD-L1-positive stage IV non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03469960
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Conditions: Non-Small Cell Lung Cancer Metastatic
- Interventions: Ipilimumab; Nivolumab
- Enrollment: 265
- Primary outcome: Progression Free Survival (PFS1)

## Indexed commentary on DICIPLE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 13 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=diciple-nct03469960

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03469960", "email": "<work email>"}; the inbox owner confirms by the emailed link.